摘要
目的:探究分析在心律失常患者治疗中运用普罗帕酮与美托洛尔的效果.方法:选择2021年7月--2022年7月我院收治心律失常患者100例,按照随机数字表方式分为对照组(普罗帕酮治疗,n=50例)和研究组(普罗帕酮与美托洛尔治疗,n=50例),对比两组临床疗效、治疗前后24h动态心电图变化、血清学指标以及不良反应发生率.结果:研究组临床总疗效率为92.00％,高于对照组,P ＜ 0.05;研究组治疗后房性早搏、短阵室速、室性早搏、短阵房速的发作次数各为(581.15±16.47)、(1.42±0.29)、(4
Abstract
Objective To explore and analyze the effect of propafenone and metoprolol in the treatment of arrhythmia.Methods: A total of 100 patients with arrhythmia in our hospital from July 2021 to July 2022 were randomly divided into control group (propafenone treatment, n=50 cases) and research group (propafenone and metoprolol treatment, n=50 cases).The clinical efficacy, 24h dynamic electrocardiogram changes before and after treatment, serological indicators and the incidence of adverse reactions were compared between the two groups.Results: The total clinical efficacy rate of treatment group was 92.00％, which was higher than that of the control group (P ＜ 0.05).The attack times of atrial premature beat, shortcircuit ventricular velocity, ventricular premature beat and short-circuit atrial velocity in the treatment group were (581.15±16.47), (1.42±0.29), (489.95±15.16) and (2.18±0.23) times respectively, which were less than those in the control group (P ＜ 0.05).The levels of hs-CRP and BNP in the research group after treatment were (7.38±0.83)mg/L/L and (105.84±10.52)pg/ml/mL, respectively, which were lower than those in the control group (P ＜ 0.05).The adverse reaction rate of the study group during the treatment was 26.00％, and there was no difference as compared with the control group (P ＞ 0.05).Conclusion: The efficacy of propafenone and metoprolol in the treatment of patients with arrhythmia is reliable, it can effectively reduce the attack times of arrhythmia and adjust the serum indicators.At the same time, it does not significantly increase the adverse reactions of drugs, which is worthy of promotion.
万方数据